Display options
Cite
Vogl TJ, Emam A, Naguib NN, et al. How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?. Viszeralmedizin. 2015;31(6):406-13doi: 10.1159/000440677.
Vogl, T. J., Emam, A., Naguib, N. N., Eichler, K., & Zangos, S. (2015). How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?. Viszeralmedizin, 31(6), 406-13. https://doi.org/10.1159/000440677
Vogl, Thomas J, et al. "How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?." Viszeralmedizin vol. 31,6 (2015): 406-13. doi: https://doi.org/10.1159/000440677
Vogl TJ, Emam A, Naguib NN, Eichler K, Zangos S. How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?. Viszeralmedizin. 2015 Dec;31(6):406-13. doi: 10.1159/000440677. Epub 2015 Dec 01. PMID: 26889144; PMCID: PMC4748795.
Copy Download .nbib Format: NLM
Share it on

Viszeralmedizin. 2015 Dec;31(6):406-13. doi: 10.1159/000440677. Epub 2015 Dec 01.

How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?.

Viszeralmedizin

Thomas J Vogl, Ahmed Emam, Nagy N Naguib, Katrin Eichler, Stefan Zangos

Affiliations

  1. Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main, Germany.
  2. Institute for Diagnostic and Interventional Radiology, University Hospital Frankfurt, Johann Wolfgang Goethe University, Frankfurt am Main, Germany; Department of Diagnostic and Interventional Radiology, University of Alexandria, Alexandria, Egypt.

PMID: 26889144 PMCID: PMC4748795 DOI: 10.1159/000440677

Abstract

BACKGROUND: The purpose of this review is to demonstrate the clinical indications, technical developments, and outcome of liver-directed therapies in interventional oncology of non-colorectal liver metastases.

METHODS: Liver-directed therapies are classified into vascular transarterial techniques such as chemoperfusion (TACP), chemoembolization (TACE), radioembolization (selective internal radiation therapy (SIRT)), and chemosaturation, as well as thermal ablation techniques like microwave ablation (MWA), radiofrequency ablation (RFA), laser-induced thermotherapy (LITT), cryotherapy, and irreversible electroporation (IRE). The authors searched the database PubMed using the following terms: 'image-guided tumor ablation', 'thermal ablation therapies', 'liver metastases of uveal melanoma', 'neuroendocrine carcinoma', 'breast cancer', and 'non-colorectal liver metastases'.

RESULTS: Various combinations of the above-mentioned therapy protocols are possible. In neuroendocrine carcinomas, oligonodular liver metastases are treated successfully via thermal ablation like RFA, LITT, or MWA, and diffuse involvement via TACE or SIRT. Although liver involvement in breast cancer is a systemic disease, non-responding nodular metastases can be controlled via RFA or LITT. In ocular or cutaneous melanoma, thermal ablation is rarely considered as an interventional treatment option, as opposed to TACE, SIRT, or chemosaturation. Rarely liver-directed therapies are used in pancreatic cancer, most likely due to problems such as biliary digestive communications after surgery and the risk of infections. Rare indications for thermal ablation are liver metastases of other primary cancers like non-small cell lung, gastric, and ovarian cancer.

CONCLUSION: Interventional oncological techniques play a role in patients with liver-dominant metastases.

Keywords: Laser ablation; Microwave ablation; Non-colorectal liver metastases; Radiofrequency ablation

References

  1. Surgery. 2010 Dec;148(6):1288-93; discussion 1293 - PubMed
  2. Chem Phys Lipids. 2012 May;165(4):424-37 - PubMed
  3. Anticancer Res. 2013 Aug;33(8):3355-8 - PubMed
  4. Eur Radiol. 2013 Mar;23(3):797-804 - PubMed
  5. Radiographics. 2000 Jan-Feb;20(1):9-27 - PubMed
  6. J Vasc Interv Radiol. 2012 May;23(5):635-41 - PubMed
  7. Acta Radiol Short Rep. 2014 Jan 23;3(1):2047981613499753 - PubMed
  8. Radiology. 2002 May;223(2):331-7 - PubMed
  9. Cardiovasc Intervent Radiol. 2012 Apr;35(2):334-42 - PubMed
  10. Oncology. 2014;86(1):24-32 - PubMed
  11. Pol J Radiol. 2011 Jul;76(3):26-32 - PubMed
  12. Acad Radiol. 1996 Aug;3(8):636-44 - PubMed
  13. AJR Am J Roentgenol. 2000 Dec;175(6):1619-25 - PubMed
  14. Radiology. 2003 Oct;229(1):171-5 - PubMed
  15. Radiology. 1995 Mar;194(3):731-7 - PubMed
  16. J Cancer Res Clin Oncol. 2007 Mar;133(3):177-84 - PubMed
  17. Invest Radiol. 2013 Jun;48(6):406-12 - PubMed
  18. Diagn Interv Radiol. 2015 Jan-Feb;21(1):54-9 - PubMed
  19. Eur J Radiol. 2009 Dec;72(3):517-28 - PubMed
  20. Digestion. 2003;68(2-3):94-101 - PubMed
  21. Cancer Invest. 2006 Jun-Jul;24(4):444-56 - PubMed
  22. Radiology. 2014 Oct;273(1):241-60 - PubMed
  23. Eur J Radiol. 2014 Oct;83(10):1804-10 - PubMed
  24. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1756-60 - PubMed
  25. Melanoma Res. 2010 Jun;20(3):191-6 - PubMed
  26. Radiology. 2003 Nov;229(2):457-64 - PubMed
  27. J Vasc Interv Radiol. 2006 Jul;17 (7):1117-24 - PubMed
  28. Surgery. 2007 Jul;142(1):10-9 - PubMed
  29. Acad Radiol. 1995 May;2(5):399-404 - PubMed
  30. Radiology. 2002 Nov;225(2):367-77 - PubMed
  31. Rofo. 2007 Nov;179(11):1181-8 - PubMed
  32. Rofo. 2014 Oct;186(10):937-44 - PubMed
  33. In Vivo. 2009 Jan-Feb;23 (1):131-7 - PubMed
  34. Eur J Radiol. 2010 Jun;74(3):e38-44 - PubMed
  35. Pancreas. 2011 Nov;40(8):1271-5 - PubMed
  36. Melanoma Res. 2005 Aug;15(4):297-304 - PubMed
  37. J Nucl Med. 2014 Sep;55(9):1404-10 - PubMed
  38. J Vasc Interv Radiol. 2008 Jun;19(6):855-61 - PubMed
  39. Rofo. 2003 May;175(5):695-704 - PubMed

Publication Types